Cambridge spin-out Xampla adds sustainability leader as Chair; earns B Corp status
A former board member of one of the world’s biggest companies and White House climate change advisor has joined a Cambridge University start-up making plastic from peas.
First subject dosed with ZF874, a potential disease-modifying treatment for alpha-1-antitrypsin deficiency
Z Factor Ltd, a Cambridge-based drug development company spun out of the University of Cambridge, announced that the first human volunteer was dosed today with ZF874, its novel treatment for alpha-1-antitrypsin deficiency (AATD).
Cambridge Enterprise leads strategic funding round for Bond180
Bond180, a provider of technology solutions for primary fixed income markets, has announced completion of a strategic funding round. The round involved follow-on investment from Cambridge Enterprise, joined by technology partners, strategic angels, and venture investors.
Research England backs two initiatives to boost economic value realised from university research
Research England has awarded two grants, totalling £1.5 million, to support two programmes working to dramatically increase the economic value and social impacts derived from university research, both internationally and in the UK. The funds will be administered by the University of Cambridge.
Cambridge spin-out PharmEnable raises £1.8m for drug discovery expansion
PharmEnable, a Cambridge-based drug discovery company using advanced medicinal chemistry and AI-enabled approaches to design the next generation of highly complex and specific drug candidate molecules, announces it has closed a £1.8 million seed financing to support its transition into a drug development company.
University spin-out Flusso raises $5.7m Series A to disrupt $8bn flow monitoring market
Semiconductor company Flusso has raised a $5.7 million Series A funding round to scale up production of the world’s smallest flow sensor. The round was led by existing investor Parkwalk Advisors and new investor Foresight Williams Technology EIS Fund, with participation from Cambridge Enterprise, 24 Haymarket, Martlet, and Cambridge Angels.
Cambridge spin-out Poro Technologies announces £1.5m seed round
Poro Technologies, the Gallium Nitride (GaN) material technology developer and a recent spin-out from the University of Cambridge, has closed a £1.5 million seed round investment to develop a pilot plant in Cambridge and its first major products. The seed round was co-led by Cambridge Enterprise, the commercialisation arm of the University of Cambridge, and IQ Capital Partners, with the…
Cambridge spin-out Kalium Health secures £950k investment
Kalium Health, which aims to transform the lives of patients with kidney disease, announces the completion of a seed investment round. Cambridge Enterprise led the over-subscribed round with participation from Kidney Research UK, Cambridge Angels and Martlet Capital, the investment arm of Marshall of Cambridge Group.
Ajay Chowdhury named Chair of Cambridge Enterprise Board
Ajay Chowdhury has been named Chair of the Board of Cambridge Enterprise. He assumed leadership of the Board in January, overseeing the strategy of Cambridge Enterprise, which is tasked with supporting the commercialisation of the ideas that emerge from the University.
The University of Cambridge launches its seventh Enterprise Fund, investing in companies that commercialise scientific and technological discoveries at the university
The University of Cambridge has launched its seventh Enterprise Fund, managed by university spinout fund manager Parkwalk in conjunction with Cambridge Enterprise, the University's Technology Transfer Office.
Riverlane, a quantum computing software developer, raises £3.25m
Riverlane, Europe’s most advanced quantum computing software developer, has raised £3.25m in seed funding, led by venture capital investors Cambridge Innovation Capital (CIC) and Amadeus Capital Partners, with the participation of Cambridge Enterprise.
Making progress towards a materials revolution
A small consultancy agreement facilitated by Cambridge Enterprise in 2012 led to some surprising results – and a major project that could prove world-changing.
Green material for cooling identified; Cambridge Enterprise to commercialise
Researchers from the UK and Spain have identified an eco-friendly solid that could replace the inefficient and polluting fluids used in most refrigerators and air conditioners.
Cambridge Enterprise refreshes its Board with five new members
Cambridge Enterprise, the commercialisation arm of the University of Cambridge, welcomes three new Directors and two new Advisors to its governing body. Together they bring a range of new perspectives to the Board, including representation from the Arts, Humanities and Social Sciences and an international outlook.
One thing leads to another in the search for more efficient LEDs
A small consultancy project enabled by Cambridge Enterprise has blossomed over a short space of time into a major new initiative to develop and commercialise greener and more efficient light emitting diodes (LEDs).
Leading US university tech transfer office heads meet with government and top UK universities
Two of the most innovative US universities, along with their UK counterparts, will meet with the minister and innovation and industrial strategy leaders from UK government today (Monday 25 February).
Leading Cambridge entrepreneur takes up residence at Cambridge Enterprise
Paul Bailey, one of Cambridge’s most influential entrepreneurs and Executive Chairman of Bailey Fisher, has joined Cambridge Enterprise, the commercialisation arm of the University of Cambridge, as an Entrepreneur in Residence.
Cambridge Enterprise and Maxwell Centre at 2019 North American International Auto Show
Cambridge Enterprise and the Maxwell Centre are jointly hosting the University of Cambridge exhibit at AutoMobili-D 2019, within the North American International Auto Show in Detroit yhis week (14-17 January).
Morphogen-IX raises £18.4m in a Series B financing
Morphogen-IX Ltd, a University of Cambridge spin-out biotechnology company focused on the development of bone morphogenetic proteins (BMPs) for the treatment of pulmonary arterial hypertension (PAH), has announced completion of a £18.4 million ($23.2m) round of financing.
Synthetic biology start-up Colorifix raises $3m to scale its textile dyeing solution
Colorifix, a company that has developed the first commercial biological dyeing process, has raised a Series A round of $3 million from impact and strategic investors with strong links to the fashion industry. The round was led by Challenger 88, with participation from Cambridge Enterprise, H&M CO:LAB (part of H&M Group) and Primera Impact.
Cambridge spin-out Morphogen-IX announces its clinical development candidate
Morphogen-IX Ltd, a biotechnology spin-out from Cambridge Enterprise that is focused on the development of bone morphogenetic proteins (BMPs) for the treatment of pulmonary arterial hypertension (PAH), announced the nomination of its clinical development candidate and initiation of formal preclinical development.
Poro Technologies wins the 2018 Postdoc Business Plan Competition
Poro Technologies, which is developing next-generation LED technology, has won the £20,000 first prize in the 2018 Cambridge Enterprise and Entrepreneurial Postdocs of Cambridge (EPOC) Postdoc Business Plan Competition.
Astellas announces acquisition of Cambridge spin-out Quethera
Astellas Pharma Inc. and Quethera Limited have announced that Astellas has acquired Quethera, a gene therapy company headquartered in the United Kingdom that is focused on developing novel treatments for ocular disorders, such as glaucoma.
Semi-finalists named in Postdoc Business Plan Competition
Twelve semi-finalists have been named in the 2018 Postdoc Business Plan Competition run by Cambridge Enterprise in conjunction with the Entrepreneurial Postdocs of Cambridge (EPOC).
Morphogen-IX announces appointment of CEO and SAB members
Morphogen-IX Ltd, a preclinical biotechnology company focused on the development of bone morphogenetic proteins for the treatment of pulmonary arterial hypertension (PAH), has announced the appointment of Professor Nick Morrell as CEO. Morrell co-founded the company in 2015 based on research from his lab at the University of Cambridge.